Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
National Cancer Institute Search for Clinical Trials
European Medicines Agency
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Thrombotic microangiopathy associated with interferon beta.
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Biogen Idec's long-acting beta interferon moves ahead in MS
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Generic interferon-beta
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Biogen Reports Another Tecfidera PML Case
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Decreased microglial activation in MS patients treated with glatiramer acetate.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.

Pages